Abstract
In our facility, three patients developed tacrolimus (TAC)-induced renal dysfunction after allogeneic hemopoietic stem cell transplantation, although trough levels of TAC were within therapeutic ranges. They received an oral agent of slow-release TAC once a day instead of a regular form oral TAC twice a day. Following treatment with the prolonged-release agent, serum creatinine levels decreased and graft-versus-host disease (GVHD) did not occur. Use of this slow-release formulation may avoid toxic peak concentrations of TAC without the development of GVHD.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Acute Kidney Injury / chemically induced*
-
Acute Kidney Injury / prevention & control*
-
Adult
-
Aged
-
Delayed-Action Preparations
-
Female
-
Graft vs Host Disease / prevention & control
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects*
-
Immunosuppressive Agents / pharmacokinetics
-
Leukemia, Myeloid, Acute / therapy*
-
Male
-
Middle Aged
-
Tacrolimus / administration & dosage
-
Tacrolimus / adverse effects*
-
Tacrolimus / pharmacokinetics
Substances
-
Delayed-Action Preparations
-
Immunosuppressive Agents
-
Tacrolimus